Cure8 research brief
A controlled trial found low-dose naltrexone did not induce endoscopic or clinical remission in Crohn's disease, but it showed a possible benefit for reducing fatigue. Patients seeking symptom relief without immunosuppression may find the fatigue signal of interest, though it is preliminary.
Adults with Crohn's disease, clinicians treating IBD, and researchers studying symptom-focused therapies or fatigue in IBD
This study does not support using low-dose naltrexone to induce clinical or endoscopic remission in Crohn's disease. The finding of reduced fatigue is preliminary, from a small, prematurely terminated trial, and should be viewed as hypothesis-generating.
Larger, specifically designed studies would be needed to confirm any benefit for fatigue before changing clinical practice.
The trial was small and stopped early for futility; fatigue benefit came from a patient-reported questionnaire and requires confirmation in larger studies. The source is a peer-reviewed journal abstract.
Review the original publication for the complete reporting, methods, and context.
Conflict statement: Declarations. Conflict of interest: ACV has served on the advisory boards for Takeda, Janssen, Bristol Myers Squibb, Abbvie, Pfizer, and Galapagos and has received unrestricted research grants from Takeda, Janssen, Abbvie, Lilly, and Pfizer, outside the submitted work; GF has received speaker fees from Abbvie and Jansen; RW received speaker fees from Ferring, Pfizer and Janssen. All other authors declare no conflicts of interest for the submitted work.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This press release reports phase 2 evidence that a new experimental antibody (duvakitug) showed clinical, endoscopic, and histologic improvements in both UC and Crohn’s disease, which could lead to a new treatment option...
Children with Crohn’s disease have fewer FDA‑approved advanced treatment options than adults, so clinicians and families often must choose among off‑label therapies with limited pediatric evidence.
Patients with IBD often have joint and skin comorbidities that drive symptoms and treatment choices.
